Cargando…

Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity

BACKGROUND: Rituximab is widely used to treat autoimmunity but clinical response varies. Efficacy is determined by the efficiency of B-cell depletion, which may depend on various Fc gamma receptor (FcγR)-dependent mechanisms. Study of FcγR is challenging due to the complexity of the FCGR genetic loc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robinson, James I., Md Yusof, Md Yuzaiful, Davies, Vinny, Wild, Dawn, Morgan, Michael, Taylor, John C., El-Sherbiny, Yasser, Morris, David L., Liu, Lu, Rawstron, Andy C., Buch, Maya H., Plant, Darren, Cordell, Heather J., Isaacs, John D., Bruce, Ian N., Emery, Paul, Barton, Anne, Vyse, Timothy J., Barrett, Jennifer H., Vital, Edward M., Morgan, Ann W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663864/ https://www.ncbi.nlm.nih.gov/pubmed/36371989 http://dx.doi.org/10.1016/j.ebiom.2022.104343

Ejemplares similares

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2017)

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome
por: Pepple, Sophanit, et al.
Publicado: (2022)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
por: Hassan, Sabih Ul, et al.
Publicado: (2020)

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2023)

Early intervention in systemic lupus erythematosus: time for action to improve outcomes and health-care utilization
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2021)

Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2018)

B Cell Tetherin: A Flow Cytometric Cell‐Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus
por: El‐Sherbiny, Yasser M., et al.
Publicado: (2020)

Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity
por: Psarras, Antonios, et al.
Publicado: (2020)

Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2022)

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus
por: Mahmoud, Khaled, et al.
Publicado: (2019)

FcγRIIIa Expression on Monocytes in Rheumatoid Arthritis: Role in Immune-Complex Stimulated TNF Production and Non-Response to Methotrexate Therapy
por: Cooper, Dawn L., et al.
Publicado: (2012)

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
por: Massey, Jonathan, et al.
Publicado: (2018)

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature
por: Shalbaf, Mohammad, et al.
Publicado: (2019)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study
por: Mahmoud, Khaled, et al.
Publicado: (2021)

Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B
por: Morgan, Ann W, et al.
Publicado: (2006)

Replication of Association of the PTPRC Gene With Response to Anti–Tumor Necrosis Factor Therapy in a Large UK Cohort
por: Plant, Darren, et al.
Publicado: (2012)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis
por: Cordingley, Lis, et al.
Publicado: (2014)

Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Bluett, James, et al.
Publicado: (2015)

IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia
por: Schmidt, David E., et al.
Publicado: (2020)

Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels
por: Jani, Meghna, et al.
Publicado: (2016)

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
por: Jani, Meghna, et al.
Publicado: (2017)

The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort
por: Smith, Samantha Louise, et al.
Publicado: (2017)

Prediction of treatment response in rheumatoid arthritis patients using genome‐wide SNP data
por: Cherlin, Svetlana, et al.
Publicado: (2018)

Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples
por: Smith, Samantha Louise, et al.
Publicado: (2015)

Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis
por: Nair, Nisha, et al.
Publicado: (2020)

A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features
por: El-Sherbiny, Y. M., et al.
Publicado: (2018)

Publisher Correction: A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features
por: El-Sherbiny, Y. M., et al.
Publicado: (2018)

Previously reported PDE3A–SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort
por: Smith, Samantha Louise, et al.
Publicado: (2016)

Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: OIiver, James, et al.
Publicado: (2021)

Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: Oliver, James, et al.
Publicado: (2021)

Herpetic tracheitis in association with rituximab therapy
por: Thong, Lorraine, et al.
Publicado: (2016)

Association of FCGR2A and Fc gamma receptor haplotypes with Spanish polymyalgia rheumatica and giant cell arteritis
por: Morgan, AW, et al.
Publicado: (2005)

Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Plant, Darren, et al.
Publicado: (2012)

Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Bluett, J, et al.
Publicado: (2014)

Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score
por: Gilani, Syed SA, et al.
Publicado: (2020)

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kh9msn03al9argue6v8gp704ck